Your session is about to expire
← Back to Search
Liposomal bupivacaine for Local Anesthesia
Study Summary
This trial is testing whether using liposomal bupivacaine, an anesthetic, during a major extremity amputation can decrease pain and the use of opioids afterwards, as well as the length of the hospital stay.
- Local Anesthesia
- Amputation
- Opioid Use Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA granted its sanction to Liposomal bupivacaine?
"Liposomal bupivacaine has gone through the necessary levels of assessment to receive approval, so it was scored 3 for safety."
Have any prior studies been conducted involving Liposomal bupivacaine?
"At present, there are 109 ongoing clinical trials exploring the uses of Liposomal bupivacaine. Of these studies, 18 have reached Phase 3 and most are located in Philadelphia, Pennsylvania; however, 144 sites worldwide are conducting research on this drug therapy."
Are there still vacancies left in the clinical trial?
"The details of this clinical trial, initially posted 4/21/2020 and recently amended 5/26/2022, are currently being advertised with the goal of recruiting participants."
What symptoms does Liposomal bupivacaine usually address?
"Liposomal bupivacaine is the most commonly used treatment for pemphigus and has also been known to address acute nonspecific tenosynovitis, general anesthesia, and lupus erythematosus cell."
What is the cap on patient participation in this trial?
"Affirmative. Clinicaltrials.gov attests that this medical experiment, which was originally posted on April 21st 2020, is actively looking for participants. The research team needs to find 50 individuals from one specific site to complete the study."
Share this study with friends
Copy Link
Messenger